RxDoctor Payments Data

David Gallo, MD

Cardiovascular Disease · Middletown, CTNPI 1609984509

Payments from drug & device makers

$1,671in general payments, 2019–2025

Across 96 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$255
  • Regeneron Healthcare Solutions, Inc.$241
  • Novartis$163
  • AstraZeneca$121
  • Boehringer Ingelheim$112
  • Pfizer$108
  • plus $671 from 16 others

What the payments were for

  • Food & beverage$1,62797%
  • Education$433%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,671 in reported general payments places this provider in the 50th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$179,435
Medicare patients
1,212
Services billed
2,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban554$795,191
XareltoRivaroxaban159$214,166
EntrestoSacubitril/Valsartan62$95,197
JardianceEmpagliflozin61$75,828
Repatha SureclickEvolocumab26$24,336
FarxigaDapagliflozin Propanediol16$22,797
BrilintaTicagrelor25$22,164
Metoprolol Succinate412$6,549
NexletolBempedoic Acid12$6,418
Dabigatran EtexilateDabigatran Etexilate Mesylate16$4,982
Flecainide Acetate83$3,992
Diltiazem 24hr Er (Cd)Diltiazem Hcl124$3,356
PradaxaDabigatran Etexilate Mesylate11$3,101
Rosuvastatin Calcium235$2,414
Atorvastatin Calcium230$2,386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$108$795,191554 claims
Johnson & JohnsonXarelto$255$214,166159 claims
NovartisEntresto$163$95,19762 claims
Boehringer IngelheimJardiance, Pradaxa$112$78,93072 claims
AstraZenecaFarxiga, Brilinta$121$44,96141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Middletown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →